Why complex case management and access matters more now

For commercial teams, access is no longer a simple sequence of benefits verification, prior authorization, and first dispense. The hardest cases are the ones where patients face multiple barriers at once: restrictive coverage rules, high out-of-pocket costs, specialty pharmacy routing, therapy education needs, or repeated reauthorizations. That complexity matters because delays are not just administrative. In the American Medical Association’s 2025 prior authorization survey, 95% of physicians said prior authorization delays necessary care, and 79% said patients abandon treatment because of authorization challenges. A 2023 systematic review of specialty drug utilization reached a similar conclusion on affordability, finding that patient cost sharing above $100 was associated with specialty drug abandonment rates ranging from 32% to 75% in some studies.

That is why complex case management and access should be thought of as an operating model, not a niche function. The question is not whether a patient qualifies as “complex” in a clinical sense. It is whether the journey from prescription to persistence includes enough friction that a standard, linear support workflow is likely to fail. In commercial patient support, that often means the case needs tighter triage, more proactive outreach, and a more connected view across reimbursement, specialty pharmacy, affordability, and ongoing patient support.

What makes a case complex on the commercial side

A commercially complex case usually has one or more repeating barriers. A benefits investigation may be complete, but prior authorization requirements change. A prescription may be approved, but the patient discovers the cost share is unaffordable. A therapy may be shipped, but reauthorization or a plan change later interrupts treatment. These are not rare exceptions in specialty access. In a 2026 study from Vanderbilt, patients whose specialty prescriptions went to external specialty pharmacies had higher primary medication nonadherence than those using an integrated health system specialty pharmacy, 9.9% versus 6.5%, along with a slower median turnaround time of 4 days versus 3 days. A separate matched-cohort study found that time to treatment initiation was 6 days longer when specialty prescriptions were transferred externally.

Those studies are useful because they show where access breaks down. The barriers are not always clinical. They are often coordination problems: who owns the next step, who sees the delay, who explains the issue to the patient, and who routes the case into the right affordability or dispensing pathway before it becomes an abandonment risk. For commercial leaders, that is the real meaning of complex case management and access. It is less about labeling certain patients and more about identifying when fragmented handoffs create preventable friction.

What stronger case management looks like in practice

A stronger model starts with triage logic. Instead of treating every referral the same, programs can identify patients at higher risk for access failure early: high cost-sharing exposure, Medicare or accumulator-related affordability questions, expected prior authorization difficulty, non-integrated specialty pharmacy routing, or the need for repeated follow-up because of therapy complexity. The goal is not more outreach for its own sake. The goal is to assign the right level of support before the case becomes a delay. Lower cost sharing and patient support interventions are associated with faster fills, better initiation, and better persistence.

From there, complex case management works best when one function can see the whole journey. In a financial navigation pilot in oncology, patients received monthly contact over six months, and the navigation team helped with issues such as insurance coverage applications, disability applications, housing, and transportation. The program was feasible to run and reduced anxiety about costs in a meaningful subset of patients. In a separate quality improvement project at Memorial Sloan Kettering, a simple electronic referral mechanism generated 718 orders for 670 unique patients across 55 treatment areas and helped connect referred patients to at least $850,000 in financial aid. The lesson is not that every commercial program should copy oncology navigation. It is that structured escalation pathways help surface needs that otherwise stay hidden until therapy is delayed or dropped.

Why technology matters when the journey is not linear

Technology helps most when it reduces fragmentation. Commercial teams often talk about “visibility,” but in practice that means something specific: seeing where a case sits now, what barrier is unresolved, what documentation is missing, when a reauthorization clock starts, and whether the patient has actually moved from approval to dispense. When systems cannot do that, the patient ends up repeating information and staff spend time recreating context instead of resolving the barrier. The evidence on patient-facing tools points in the same direction. In a JAMA Network Open study, adults with diabetes who had mobile patient portal access along with computer portal access showed better medication adherence and glycemic control than patients without that mobile access. The point is not that a portal alone solves access. It is that timely visibility and easier communication can improve follow-through.

Broader patient support also supports an integrated approach. A targeted systematic review of patient support programs found that among studies measuring adherence, about two-thirds reported at least one positive adherence outcome, and about two-thirds of studies measuring humanistic outcomes reported improvement as well. That does not mean every support intervention works equally well. It does suggest that when support is structured, intentional, and connected to real barriers, it is more likely to improve the outcomes commercial teams actually care about after therapy start.

How commercial teams should measure success

The most useful measurement framework for complex case management and access follows the patient across handoffs instead of grading each function separately. Time to benefits determination, prior authorization approval rate, time from approval to first dispense, primary medication nonadherence, affordability pathway resolution, reauthorization completion, and persistence after therapy start are all more informative than call volume or case counts alone. Specialty pharmacy studies increasingly use turnaround time and primary medication nonadherence as access markers, while patient support and financial assistance studies show why persistence, adherence, and successful resource connection matter downstream. Together, those measures create a more honest picture of whether a program is reducing friction or simply documenting it.

Conclusion

Complex case management and access has become a core commercial capability because the biggest threats to therapy initiation and persistence are often operational, not clinical. High cost sharing, prior authorization delays, fragmented specialty pharmacy workflows, and hidden affordability needs can all turn a valid prescription into a lost patient. The strongest programs recognize complexity early, coordinate work across functions, and measure whether support actually changes time to therapy and persistence.